Immunomodulatory properties and therapeutic application of mesenchymal stem cells

Clinical and Experimental Immunology

Volumn 164, Issue 1, 2011, Pages 1-8

  Shi, M ^a   Liu, Z W ^a   Wang, F S ^a  

^a BEIJING 302 HOSPITAL   (China)

Author keywords

Immunosuppression; Mesenchymal stem cells; Review; Therapeutic applications

Indexed keywords

BASILIXIMAB; CD40 LIGAND; CXCL13 CHEMOKINE; GAMMA INTERFERON; HLA G ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEUTRALIZING ANTIBODY; NITRIC OXIDE; PROSTAGLANDIN E2; RABBIT THYMOCYTE ANTIBODY; STAT5 PROTEIN; STROMAL CELL DERIVED FACTOR 1; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; AMYOTROPHIC LATERAL SCLEROSIS; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; DENDRITIC CELL; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INHIBITION KINETICS; LOW DRUG DOSE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NATURAL KILLER CELL; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

B-LYMPHOCYTES; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; HUMANS; KILLER CELLS, NATURAL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES;

EID: 79952505963     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04327.x     Document Type: Review

References (71)

1. Herzog EL, Chai L, Krause DS. Plasticity of marrow-derived stem cells. Blood 2003; 102:3483-93.
2. Prockop DJ, Gregory CA, Spees JL. One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues. Proc Natl Acad Sci USA 2003; 100 (Suppl. 1):11917-23.
3. Gronthos S, Franklin DM, Leddy HA, Robey PG, Storms RW, Gimble GM. Surface protein characterization of human adipose tissue-derived stromal cells. J Cell Physiol 2001; 189:54-63.
4. Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000; 109:235-42.
5. in't Anker PS, Scherjon SA, Klejiburg-van der Keur C etal. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood 2003; 102:1548-9.
6. in't Anker PS, Noort WA, Kruisselbrink AB etal. Nonexpanded primary lung and bone marrow-derived mesenchymal stem cells promote the engraftment of umbilical cord blood-derived CD34(+) cells in the NOD/SCID mice. Exp Hematol 2003; 31:881-9.
7. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968; 6:230-47.
8. Friedenstein AJ. Precursor cells of mechanocytes. Int Rev Cytol 1976; 47:327-59.
9. Pittenger MF, Mackay AM, Beck SC etal. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143-7.
10. Reyes M, Lund T, Lenvik T, Aguiar D, Koodie L, Verfaillie CM. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001; 98:2615-25.
11. Horwitz EM, Le Blanc K, Dominici M etal. Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy 2005; 7:393-5.
12. Dominici M, Le Blanc K, Mueller I etal. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8:315-17.
13. Rasmusson I. Immune modulation by mesenchymal stem cells. Exp Cell Res 2006; 312:2169-79.
14. Di Nicola M, Carlo-Stella C, Magni M etal. Human bone marrow stromal cells suppress T lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99:3838-43.
15. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57:11-20.
16. Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 2003; 171:3426-34.
17. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003; 75:389-97.
18. Bartholomew A, Sturgeon C, Siatskas M etal. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30:42-8.
19. Djouad F, Plence P, Bony C etal. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102:3837-44.
20. Krampera M, Glennie S, Dyson J etal. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101:3722-9.
21. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105:2821-7.
22. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24:74-85.
23. Jiang XX, Zhang Y, Liu B etal. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105:4120-6.
24. Krampera M, Cosmi L, Angeli R etal. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24:386-98.
25. Groh ME, Maitra B, Szekely E, Koc ON. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 2005; 33:928-34.
26. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76:1208-13.
27. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase mediated tryptophan degradation. Blood 2004; 103:4619-21.
28. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105:1815-22.
29. Sato K, Ozaki K, Oh I etal. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109:228-34.
30. Bingisser RM, Tilbrook PA, Holt PG, Kees UR. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol 1998; 160:5729-34.
31. Ding Y, Xu D, Feng G, Bushell A, Muschel RJ, Wood KJ. Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes 2009; 58:1797-806.
32. Carosella ED, Moreau P, Le Maoult J, Le Discorde M, Dausset J, Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol 2003; 81:199-252.
33. Selmani Z, Naji A, Zidi I etal. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26:212-22.
34. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 2000; 28:875-84.
35. Zappia E, Casazza S, Pedemonte E etal. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T cell anergy. Blood 2005; 106:1755-61.
36. González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 2009; 60:1006-19.
37. Lim JH, Kim JS, Yoon IH etal. Immunomodulation of delayed-type hypersensitivity responses by mesenchymal stem cells is associated with bystander T cell apoptosis in the draining lymph node. J Immunol 2010; 185:4022-9.
38. Maccario R, Podesta M, Moretta A etal. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005; 90:516-25.
39. Sensebé L, Krampera M, Schrezenmeier H, Bourin P, Giordano R. Mesenchymal stem cells for clinical application. Vox Sang 2010; 98:93-107.
40. Ren G, Su J, Zhang L etal. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009; 27:1954-62.
41. Le Blanc K, Ringdén O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007; 262:509-25.
42. Augello A, Tasso R, Negrini SM etal. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005; 35:1482-90.
43. Corcione A, Benvenuto F, Ferretti E etal. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107:367-72.
44. Deng W, Han Q, Liao L, You S, Deng H, Zhao RC. Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA Cell Biol 2005; 24:458-63.
45. Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007; 149:353-63.
46. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006; 107:1484-90.
47. Poggi A, Prevosto C, Massaro AM etal. Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J Immunol 2005; 175:6352-60.
48. Moretta A, Bottino C, Vitale M etal. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001; 19:197-23.
49. Prigione I, Benvenuto F, Bocca P, Battistini L, Uccelli A, Pistoia V. Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells 2009; 27:693-702.
50. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 2006; 177:2080-7.
51. Zhang W, Ge W, Li C etal. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 2004; 13:263-71.
52. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte- derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009; 113:6576-83.
53. Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 2007; 83:71-6.
54. Ivanova-Todorova E, Bochev I, Mourdjeva M etal. Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Lett 2009; 126:37-42.
55. Ge W, Jiang J, Arp J, Liu W, Garcia B, Wang H. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2, 3-dioxygenase expression. Transplantation 2010; 90:1312-20.
56. Ghannam S, Pène J, Torcy-Moquet G, Jorgensen C, Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 2010; 185:302-12.
57. Tipnis S, Viswanathan C, Majumdar AS. Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO. Immunol Cell Biol 2010; 88:795-806.
58. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol 2009; 156:149-60.
59. Zhang Q, Shi S, Liu Y etal. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol 2009; 183:7787-98.
60. Sioud M, Mobergslien A, Boudabous A, Fløisand Y. Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Scand J Immunol 2010; 71:267-74.
61. Madec AM, Mallone R, Afonso G etal. Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 2009; 52:1391-9.
62. Gonzalez-Rey E, Gonzalez MA, Varela N etal. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis 2010; 69:241-8.
63. Najar M, Rouas R, Raicevic G etal. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 2009; 11:570-83.
64. Crop M, Baan CC, Korevaar SS, Ijzermans JN, Weimar W, Hoogduijn MJ. Human adipose tissue-derived mesenchymal stem cells induce explosive T-cell proliferation. Stem Cells Dev 2010; 19:1843-53.
65. Ge W, Jiang J, Baroja ML etal. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant 2009; 9:1760-72.
66. Hoogduijn MJ, Crop MJ, Peeters AM etal. Donor-derived mesenchymal stem cells remain present and functional in the transplanted human heart. Am J Transplant 2009; 9:222-30.
67. Salem HK, Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 2010; 28:585-96.
68. Ning H, Yang F, Jiang M etal. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008; 22:593-9.
69. Vianello F, Dazzi F. Mesenchymal stem cells for graft-versus-host disease: a double edged sword? Leukemia 2008; 22:463-5.
70. Liang J, Zhang H, Hua B etal. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 2010; 69:1423-9.
71. Popp FC, Renner P, Eggenhofer E etal. Mesenchymal stem cells as immunomodulators after liver transplantation. Liver Transpl 2009; 15:1192-8.